QUESTION
ANSWER
Semaglutide targets the GLP-1 receptor, while tirzepatide targets both GLP-1 and GIP receptors. Both can support weight loss, but they differ in dosing, side effects, response, and how an individual patient tolerates them.
Semaglutide targets the GLP-1 receptor, while tirzepatide targets both GLP-1 and GIP receptors. Both can support weight loss, but they differ in dosing, side effects, response, and how an individual patient tolerates them.